2-溴-1-氟-4-异硫氰基苯 | 710351-24-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-1-氟-4-异硫氰基苯
• 中文别名: 2-溴-1-氟-4-异氰酸苯酯
• 英文名称: 2-bromo-1-fluoro-4-isothiocyanatobenzene
• 英文别名: 3-Bromo-4-fluorophenyl isothiocyanate
• CAS: 710351-24-9
• 化学式: C₇H₃BrFNS
• 分子量: 232.076
• InChiKey: NBSZCFBECRGGJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  4-(3-amino-4-methylamino-phenoxy)-pyridine-2-carboxylic acid methylamide 、 2-溴-1-氟-4-异硫氰基苯 在 iron(III) chloride 作用下， 以 甲醇 为溶剂， 生成 4-({2-[(3-bromo-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl}oxy)-N-methylpyridine-2-carboxamide
  参考文献：
  名称：

  Substituted benzazoles and methods of their use as inhibitors of Raf kinase

  摘要：

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。

  公开号：

  US20040122237A1
• 作为产物：
  描述：

  硫光气 、 3-溴-4-氟苯胺 在 sodium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.5h， 生成 2-溴-1-氟-4-异硫氰基苯
  参考文献：
  名称：

  Substituted benzazoles and methods of their use as inhibitors of Raf kinase

  摘要：

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。

  公开号：

  US20040122237A1

文献信息

• SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Amiri Payman

  公开号：US20120288501A1

  公开（公告）日：2012-11-15

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis
  作者：Roman Šink、Izidor Sosič、Matej Živec、Raquel Fernandez-Menendez、Samo Turk、Stane Pajk、Daniel Alvarez-Gomez、Eva Maria Lopez-Roman、Carolina Gonzales-Cortez、Joaquin Rullas-Triconado、Inigo Angulo-Barturen、David Barros、Lluís Ballell-Pages、Robert J. Young、Lourdes Encinas、Stanislav Gobec

  DOI：10.1021/jm501029r

  日期：2015.1.22

  Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection. On the basis of this template, we have here explored the medicinal chemistry of truncated analogues that have only three aromatic rings. In particular, compounds 8b, 8d, 8f, 8l, and 8n show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochemical profiles in comparison with the tetracyclic analogues. From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enatiomer shows encouraging in vivo efficacy.
• US8299108B2
  申请人：——

  公开号：US8299108B2

  公开（公告）日：2012-10-30
• [EN] STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] MODULATEURS DE STIMULATEUR DE GÈNES D'INTERFÉRON (STING), ET COMPOSITIONS ET MÉTHODES ASSOCIÉES
  申请人：[en]GEODE THERAPEUTICS INC.

  公开号：WO2023158862A2

  公开（公告）日：2023-08-24

  The invention provides novel modulators of STING (Stimulator of Interferon Genes) and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as cancer, infectious and autoimmune diseases or disorders.
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。